Regeneron reports better-than-expected third-quarter results, beating earnings and revenue estimates, driven by strong Eylea HD, Dupixent and Libtayo sales.

including EASI-75 and IGA 0/1 Enrollment included approximately 15% of patients with Dupixent/anti-IL-13 treatment experience Presented analyses that characterize a BTLA transcriptomic signature in AD ...

Sanofi (SNY) has released an update. Sanofi’s Dupixent has shown promising results in a Phase 3 trial for treating chronic spontaneous ...

Good afternoon, and welcome to AbCellera's Q3 2024 business update conference call. My name is Tamia, and I will facilitate ...

Verona Pharma PLC (VRNA) reports significant sales growth for Ohtuvayre, but faces increased expenses and competition in the COPD market.

Dupixent (dupilumab) made more than €5 billion last year from its current uses in atopic dermatitis, eosinophilic asthma and chronic rhinosinusitis with nasal polyps, and EoE is one of a clutch ...

WNBA legend and all-time scoring leader Diana Taurasi shows she' passionate about off-court causes involving health and wellbeing.

U.S. drugmaker Regeneron Pharmaceuticals beat Wall Street estimates for third-quarter profit and revenue on Thursday, driven ...

Regeneron should weather the Eylea biosimilar launch storm and continue to deliver long-term shareholder value. See why REGN ...

Sanofi and Regeneron have celebrated a pair of positive clinical trials in inflammatory skin disorders with blockbuster immunology therapy Dupixent that could both lead to new indications for the ...

Regeneron reports Q3 EPS of $12.46, up 8% YoY, beating estimates. Revenue rose 11% to $3.72 billion. Key growth from Eylea, ...